|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Tang ZY: Small hepatocellular carcinoma:
current status and prospects. Hepatobiliary Pancreat Dis Int.
1:349–353. 2002.PubMed/NCBI
|
|
3
|
Giannelli G, Bergamini C, Fransvea E,
Sgarra C and Antonaci S: Laminin-5 with transforming growth
factor-beta1 induces epithelial to mesenchymal transition in
hepatocellular carcinoma. Gastroenterology. 129:1375–1383. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Marks PA, Richon VM, Miller T and Kelly
WK: Histone deacetylase inhibitors. Adv Cancer Res. 91:137–168.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jeon HW and Lee YM: Inhibition of histone
deacetylase attenuates hypoxia-induced migration and invasion of
cancer cells via the restoration of RECK expression. Mol Cancer
Ther. 9:1361–1370. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ahn MY, Kang DO, Na YJ, et al: Histone
deacetylase inhibitor, apicidin, inhibits human ovarian cancer cell
migration via class II histone deacetylase 4 silencing. Cancer
Lett. 325:189–199. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yuan JH, Yang F, Chen BF, et al: The
histone deacetylase 4/SP1/microrna-200a regulatory network
contributes to aberrant histone acetylation in hepatocellular
carcinoma. Hepatology. 54:2025–2035. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang J, Yang Y, Yang T, et al:
microRNA-22, downregulated in hepatocellular carcinoma and
correlated with prognosis, suppresses cell proliferation and
tumourigenicity. Br J Cancer. 103:1215–1220. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Prasad KN: Butyric acid: a small fatty
acid with diverse biological functions. Life Sci. 27:1351–1358.
1980. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
D’Argenio G and Mazzacca G: Short-chain
fatty acid in the human colon. Relation to inflammatory bowel
diseases and colon cancer. Adv Exp Med Biol. 472:149–158.
1999.PubMed/NCBI
|
|
11
|
Bergman EN: Energy contributions of
volatile fatty acids from the gastrointestinal tract in various
species. Physiol Rev. 70:567–590. 1990.PubMed/NCBI
|
|
12
|
Candido EP, Reeves R and Davie JR: Sodium
butyrate inhibits histone deacetylation in cultured cells. Cell.
14:105–113. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fung KY, Cosgrove L, Lockett T, Head R and
Topping DL: A review of the potential mechanisms for the lowering
of colorectal oncogenesis by butyrate. Br J Nutr. 108:820–831.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Archer SY, Meng S, Shei A and Hodin RA:
p21(WAF1) is required for butyrate-mediated growth inhibition of
human colon cancer cells. Proc Natl Acad Sci USA. 95:6791–6796.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fung KY, Brierley GV, Henderson S, et al:
Butyrate-induced apoptosis in HCT116 colorectal cancer cells
includes induction of a cell stress response. J Proteome Res.
10:1860–1869. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Davie JR: Inhibition of histone
deacetylase activity by butyrate. J Nutr. 133(Suppl 7):
2485S–2493S. 2003.PubMed/NCBI
|
|
17
|
Sun B, Liu R, Xiao ZD and Zhu X: c-MET
protects breast cancer cells from apoptosis induced by sodium
butyrate. PLoS One. 7:e301432012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tsutsumi T, Ido A, Nakao K, et al:
Reciprocal regulation of alpha-fetoprotein and albumin gene
expression by butyrate in human hepatoma cells. Gastroenterology.
107:499–504. 1994.PubMed/NCBI
|
|
19
|
Yamamoto H, Fujimoto J, Okamoto E,
Furuyama J, Tamaoki T and Hashimoto-Tamaoki T: Suppression of
growth of hepatocellular carcinoma by sodium butyrate in vitro and
in vivo. Int J Cancer. 76:897–902. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kaneko F, Saito H, Saito Y, et al:
Down-regulation of matrix-invasive potential of human liver cancer
cells by type I interferon and a histone deacetylase inhibitor
sodium butyrate. Int J Oncol. 24:837–845. 2004.PubMed/NCBI
|
|
21
|
Lok GT, Chan DW, Liu VW, et al: Aberrant
activation of ERK/FOXM1 signaling cascade triggers the cell
migration/invasion in ovarian cancer cells. PLoS One. 6:e237902011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dawson MA and Kouzarides T: Cancer
epigenetics: from mechanism to therapy. Cell. 150:12–27. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Perego P, Zuco V, Gatti L and Zunino F:
Sensitization of tumor cells by targeting histone deacetylases.
Biochem Pharmacol. 83:987–994. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ganesan A, Nolan L, Crabb SJ and Packham
G: Epigenetic therapy: histone acetylation, DNA methylation and
anti-cancer drug discovery. Curr Cancer Drug Targets. 9:963–981.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Quint K, Agaimy A, Di Fazio P, et al:
Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2
is an independent predictor of survival in HCC. Virchows Arch.
459:129–139. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Francisco R, Perez-Perarnau A, Cortes C,
Gil J, Tauler A and Ambrosio S: Histone deacetylase inhibition
induces apoptosis and autophagy in human neuroblastoma cells.
Cancer Lett. 318:42–52. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang JX, Li DQ, He AR, et al: Synergistic
inhibition of hepatocellular carcinoma growth by cotargeting
chromatin modifying enzymes and poly (ADP-ribose) polymerases.
Hepatology. 55:1840–1851. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang J, Kim TH, Ahn MY, et al: Sirtinol, a
class III HDAC inhibitor, induces apoptotic and autophagic cell
death in MCF-7 human breast cancer cells. Int J Oncol.
41:1101–1109. 2012.PubMed/NCBI
|
|
29
|
Li J, Chen J, Ricupero CL, et al: Nuclear
accumulation of HDAC4 in ATM deficiency promotes neurodegeneration
in ataxia telangiectasia. Nat Med. 18:783–790. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Weems JC, Griesel BA and Olson AL: Class
II histone deacetylases downregulate GLUT4 transcription in
response to increased cAMP signaling in cultured adipocytes and
fasting mice. Diabetes. 61:1404–1414. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Reddy SD, Pakala SB, Molli PR, et al:
Metastasis-associated protein 1/histone deacetylase 4-nucleosome
remodeling and deacetylase complex regulates phosphatase and tensin
homolog gene expression and function. J Biol Chem. 287:27843–27850.
2012. View Article : Google Scholar
|
|
32
|
Izutani Y, Yogosawa S, Sowa Y and Sakai T:
Brassinin induces G1 phase arrest through increase of p21 and p27
by inhibition of the phosphatidylinositol 3-kinase signaling
pathway in human colon cancer cells. Int J Oncol. 40:816–824.
2012.PubMed/NCBI
|
|
33
|
Catalano MG, Fortunati N, Pugliese M, et
al: Histone deacetylase inhibition modulates E-cadherin expression
and suppresses migration and invasion of anaplastic thyroid cancer
cells. J Clin Endocrinol Metab. 97:E1150–E1159. 2012. View Article : Google Scholar
|
|
34
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang J and Weinberg RA:
Epithelial-mesenchymal transition: at the crossroads of development
and tumor metastasis. Dev Cell. 14:818–829. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Iredale JP: Models of liver fibrosis:
exploring the dynamic nature of inflammation and repair in a solid
organ. J Clin Invest. 117:539–548. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zeisberg M, Yang C, Martino M, et al:
Fibroblasts derive from hepatocytes in liver fibrosis via
epithelial to mesenchymal transition. J Biol Chem. 282:23337–23347.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Nitta T, Kim JS, Mohuczy D and Behrns KE:
Murine cirrhosis induces hepatocyte epithelial mesenchymal
transition and alterations in survival signaling pathways.
Hepatology. 48:909–919. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Fransvea E, Angelotti U, Antonaci S and
Giannelli G: Blocking transforming growth factor-beta up-regulates
E-cadherin and reduces migration and invasion of hepatocellular
carcinoma cells. Hepatology. 47:1557–1566. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kaimori A, Potter JJ, Choti M, Ding Z,
Mezey E and Koteish AA: Histone deacetylase inhibition suppresses
the transforming growth factor beta1-induced
epithelial-to-mesenchymal transition in hepatocytes. Hepatology.
52:1033–1045. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yoshikawa M, Hishikawa K, Marumo T and
Fujita T: Inhibition of histone deacetylase activity suppresses
epithelial-to-mesenchymal transition induced by TGF-beta1 in human
renal epithelial cells. J Am Soc Nephrol. 18:58–65. 2007.
View Article : Google Scholar
|
|
42
|
Cavallaro U and Christofori G: Cell
adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev
Cancer. 4:118–132. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
43
|
Jovanovic V, Dugast AS, Heslan JM, et al:
Implication of matrix metalloproteinase 7 and the noncanonical
wingless-type signaling pathway in a model of kidney allograft
tolerance induced by the administration of anti-donor class II
antibodies. J Immunol. 180:1317–1325. 2008. View Article : Google Scholar
|
|
44
|
Osteen KG, Keller NR, Feltus FA and Melner
MH: Paracrine regulation of matrix metalloproteinase expression in
the normal human endometrium. Gynecol Obstet Invest. 48(Suppl 1):
S2–S13. 1999. View Article : Google Scholar
|
